Patient characteristics
. | Data . |
|---|---|
| No. patients | 15 |
| Median age, y (range) | 56 (36-66) |
| No. men/no. women | 9/6 |
| Prior hepatic metastasectomy, no. | 4 |
| Median no. prior therapies for metastatic disease (range) | 2 (1-5) |
| Median Karnofsky (range) | 70 (60-100) |
| High tumor burden, no.* | 8 |
| Median no. metastatic sites (range) | 2 (1-5) |
| Liver metastasis | 12 |
| Lung metastasis | 10 |
| Peritoneal carcinosis | 3 |
| PD status at transplantation | 15 |
| Patient/donor sex mismatch | 7 |
| Patient/donor ABO mismatch | 7 (3 minor and 4 major) |
| HLA-related donor | 15 |
| Median CD34+/Kg infused, × 106 (range) | 6.7 (2.5-11.3) |
| Patient/donor CMV status | |
| Negative/positive | 2/15 |
| Positive/positive | 13/15 |
| Hematologic toxicity | |
| ANC nadir, × 109/L (range) | 722 (519-2520) |
| Time to ANC nadir, d (range) | 9 (5-15) |
| Platelets nadir, × 109/L (range) | 119 (63-191) |
| Time to platelets nadir, d (range) | 12 (8-21) |
. | Data . |
|---|---|
| No. patients | 15 |
| Median age, y (range) | 56 (36-66) |
| No. men/no. women | 9/6 |
| Prior hepatic metastasectomy, no. | 4 |
| Median no. prior therapies for metastatic disease (range) | 2 (1-5) |
| Median Karnofsky (range) | 70 (60-100) |
| High tumor burden, no.* | 8 |
| Median no. metastatic sites (range) | 2 (1-5) |
| Liver metastasis | 12 |
| Lung metastasis | 10 |
| Peritoneal carcinosis | 3 |
| PD status at transplantation | 15 |
| Patient/donor sex mismatch | 7 |
| Patient/donor ABO mismatch | 7 (3 minor and 4 major) |
| HLA-related donor | 15 |
| Median CD34+/Kg infused, × 106 (range) | 6.7 (2.5-11.3) |
| Patient/donor CMV status | |
| Negative/positive | 2/15 |
| Positive/positive | 13/15 |
| Hematologic toxicity | |
| ANC nadir, × 109/L (range) | 722 (519-2520) |
| Time to ANC nadir, d (range) | 9 (5-15) |
| Platelets nadir, × 109/L (range) | 119 (63-191) |
| Time to platelets nadir, d (range) | 12 (8-21) |
A high tumor burden was defined by the presence of at least one of the following conditions: (1) More than 5 liver metastases, with the largest being > 5 cm or 1 single metastasis > 10 cm in diameter; (2) lung metastasis > 5 cm in diameter; (3) lymphoadenopathy > 5 cm in diameter; and (4) peritoneal carcinosis.